Cellectis Secures Final Tranche of EIB Credit Facility for CAR T-Cell Development

Cellectis SA ( (CLLS) ) has shared an announcement.

Cellectis has drawn down the final €5 million tranche under a €40 million credit facility agreement with the European Investment Bank, which will support the development of its allogeneic CAR T-cell product candidates, UCART22 and UCART20x22. As part of this agreement, Cellectis issued 611,426 warrants to the EIB, allowing the bank to subscribe for shares, which could slightly dilute existing shareholdings. This financial move is expected to enhance Cellectis’ pipeline development and strengthen its position in the gene-editing and cell therapy sector.

More about Cellectis SA

Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its pioneering gene-editing platform. The company specializes in allogeneic CAR-T immunotherapies for oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer. Additionally, Cellectis is advancing therapeutic gene editing in hemopoietic stem cells for various diseases. With 25 years of expertise in gene editing, Cellectis utilizes its TALEN® technology and PulseAgile electroporation system to harness the immune system for treating diseases with unmet needs. Headquartered in Paris, France, with locations in New York and Raleigh, the company is publicly listed on Nasdaq and Euronext Growth.

YTD Price Performance: -36.36%

Average Trading Volume: 56,912

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $140M

See more insights into CLLS stock on TipRanks’ Stock Analysis page.